Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey.

Reiner Ž, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D; EUROASPIRE III Study Group.

Atherosclerosis. 2013 Dec;231(2):300-7. doi: 10.1016/j.atherosclerosis.2013.09.020. Epub 2013 Oct 7.

PMID:
24267243
2.

Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.

Reiner Ž, De Backer G, Fras Z, Kotseva K, Tokgözoglu L, Wood D, De Bacquer D; EUROASPIRE Investigators.

Atherosclerosis. 2016 Mar;246:243-50. doi: 10.1016/j.atherosclerosis.2016.01.018. Epub 2016 Jan 13.

PMID:
26812002
3.

Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events.

Lancet. 2001 Mar 31;357(9261):995-1001.

PMID:
11293642
4.

Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey.

Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D; EUROASPIRE II Study Group.

Atherosclerosis. 2008 Apr;197(2):710-7. Epub 2007 Sep 4.

PMID:
17765905
5.

A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.

Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.

Chin Med J (Engl). 2004 Feb;117(2):163-7.

PMID:
14975195
6.

Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey.

Bruckert E, Baccara-Dinet M, Eschwege E.

Diabet Med. 2007 Apr;24(4):388-91. Epub 2007 Feb 28.

PMID:
17335463
8.

Potential for cholesterol lowering in secondary prevention of coronary heart disease in europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events.

Vanuzzo D, Pilotto L, Ambrosio GB, Pyörälä K, Lehto S, De Bacquer D, De Backer G, Wood D; EUROASPIRE Study Group.

Atherosclerosis. 2000 Dec;153(2):505-17.

PMID:
11164441
10.
11.
12.
14.

Prevalence of dyslipidaemia in apparently healthy professionals in Asaba, South South Nigeria.

Odenigbo CU, Oguejiofor OC, Odenigbo UM, Ibeh CC, Ajaero CN, Odike MA.

Niger J Clin Pract. 2008 Dec;11(4):330-5.

PMID:
19320405
15.

Dyslipidaemia in rural Australia: prevalence, awareness, and adherence to treatment guidelines in the Greater Green Triangle Risk Factor Study.

Janus ED, Tideman PA, Dunbar JA, Kilkkinen A, Bunker SJ, Philpot B, Tirimacco R, Mc Namara K, Heistaro S, Laatikainen T.

Med J Aust. 2010 Feb 1;192(3):127-32.

PMID:
20121678
16.

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.

Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group.

Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):121-37. doi: 10.1097/HJR.0b013e3283294b1d.

PMID:
19287307
17.

Lipid levels and the use of lipid-lowering agents in England and Scotland.

Primatesta P, Poulter NR.

Eur J Cardiovasc Prev Rehabil. 2004 Dec;11(6):484-8.

PMID:
15580059
18.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
19.

Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM.

Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M.

Diabetes. 1997 Aug;46(8):1354-9.

PMID:
9231662

Supplemental Content

Support Center